Programmes Industry Sessions

 

Industry Session by Ipsen

Friday, 25 November
Location: Auditorium

13.15 – 14.15 Incorporating a new treatment in advanced RCC: the evolving role of TKIs

13.15 – 13.20 Welcome 
C.N. Sternberg, Rome (IT)

13.20 – 13.35 From cytokines to targeted therapies: 20 years of progress in advanced RCC
T. Powles, London (GB)

13.35 – 13.50 Overcoming TKI resistance in advanced RCC
C.N. Sternberg, Rome (IT)

13.50 – 14.05 Guidelines in RCC: How evidencebased recommendations serve as a guide for clinical decisions
A. Bex, Amsterdam (NL)

14.05 – 14.15 Panel Discussion and close

Industry Session by Sanofi Genzyme

Friday, 25 November
Location: Auditorium

17.45 – 18.45 Redefining the management of advanced prostate cancer to optimize survival
Chair: C. Sternberg, Rome (IT)

17.45 – 17.50 Welcome and introduction
C. Sternberg, Rome (IT)

17.50 – 18.05 Are we targeting prostate cancer heterogeneity in the right way?
C. Sternberg, Rome (IT)

18.05 – 18.20 Optimizing survival in advanced hormone-sensitive prostate cancer
G. Kramer, Vienna (AT)

18.20 – 18.35 New horizons in metastatic castration-resistant prostate cancer
M. De Santis, Coventry (GB)

18.35 – 18.45 Discussion and closing remarks 
Chairman – faculty – audience

Industry Session by Janssen

Saturday, 26 November
Location: Auditorium

13.15 – 14.15 Personalizing treatment for patients with metastatic castration-resistant prostate cancer
Scientific Committee/Chairs: H. Payne, London (UK), G. Kramer, Vienna (AT)
Faculty: A. Alcaraz, Barcelona (ES)

13.15 – 13.25 Welcome and introduction
H. Payne, London (UK)

13.25 – 13.50 How do comorbidities influence our choice of treatment for our patients?
Interactive case studies, presentation of recent data, ask the audience, and panel discussions
All faculty

13.50 – 14.10 How do potential side effects influence our choice of treatment for our patients?
Interactive case studies, presentation of recent data, ask the audience, and panel discussions
All faculty

14.10 – 14.15 Summary and close